MedPath

Study of role of certain blood tests in predicting the severity of ovarian cancer

Not Applicable
Conditions
Health Condition 1: C569- Malignant neoplasm of unspecifiedovary
Registration Number
CTRI/2021/06/034317
Lead Sponsor
TATA main hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

All new cases of ovarian malignancy

Exclusion Criteria

Patients with borderline ovarian tumors

2.clinical evidence of infection or other inflammatory conditions

3. Secondary malignancy or multiple primary malignancies

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
association between CRP/albumin ratio and clinicopathological factors- <br/ ><br>Age, tumor stage and grade, histological features, ascites, lymph node involvement, tumor markersTimepoint: October 2022
Secondary Outcome Measures
NameTimeMethod
Comparison between predictive ability of CRP/albumin ratio and CA-125Timepoint: October 2022
© Copyright 2025. All Rights Reserved by MedPath